The Technical AnalystExchange: EURONEXT Industry: Diagnostics & Research
Biomerieux SA Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.10% €95.90
America/New_York / 17 mai 2024 @ 11:35
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 11 331 mill |
| EPS: | 3.01 |
| P/E: | 31.86 |
| Earnings Date: | Apr 09, 2024 |
| SharesOutstanding: | 118.15 mill |
| Avg Daily Volume: | 0.108 mill |
| RATING 2024-05-17 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 2/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | n/a | n/a | n/a | n/a | ||
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.80x |
| Company: PE 31.86 | sector: PE 17.68 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 3.87x |
| Company: PE 31.86 | industry: PE 8.23 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
€135.54 (41.34%) €39.64 |
| Date: 2024-05-19 |
| Expected Trading Range (DAY) |
|---|
|
€ 93.21 - 98.59 ( +/- 2.81%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | €95.90 (-0.10% ) |
| Volume | 0.131 mill |
| Avg. Vol. | 0.108 mill |
| % of Avg. Vol | 120.90 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BIM.PA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BIM.PA
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.